Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
vlag Nature's Sunshine Products, Inc. 30/05 15,460 USD
+1,11% 		+1,11%
vlag Navidea Biopharmaceuticals Inc 29/05 0,001 USD
-12,50% 		-12,50%
vlag Nektar Therapeutics 30/05 0,725 USD
-2,02% 		-2,02%
vlag Nkarta Inc 30/05 1,740 USD
-3,87% 		-3,87%
vlag Novabay Pharmaceuticals Inc 30/05 0,550 USD
-0,45% 		-0,45%
vlag NuCana plc 30/05 0,035 USD
-4,59% 		-4,59%
vlag Nurix Therapeutics Inc 30/05 10,630 USD
-0,09% 		-0,09%

Nieuws over “Fabricage van farmaceutische preparaten”

31/05 · New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 · Persbericht

31/05 · New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 · Persbericht

31/05 · Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date · Persbericht

30/05 · Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer · Persbericht

30/05 · Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies · Persbericht

29/05 · Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs · Persbericht

29/05 · Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day · Persbericht

29/05 · uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) · Persbericht

27/05 · Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA · Persbericht

27/05 · Galapagos Creates New Subscription Right Plan · Persbericht

27/05 · Galapagos creëert nieuw inschrijvingsrechtenplan · Persbericht

27/05 · Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June · Persbericht

27/05 · Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma · Persbericht

27/05 · Merus to Present at Upcoming Investor Conferences · Persbericht

27/05 · Europees aandelennieuws · Bolero.be

Volvo Cars schrapt 3.000 voornamelijk administratieve banen De Zweedse autofabrikant zal 3.000 voornamelijk administratieve banen schrappen als onderdeel van een herstructurering om de hoge kosten, de afname van de vraag...

27/05 · Press Release: Sanofi completes acquisition of DR-0201 · Persbericht

22/05 · Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC · Persbericht

22/05 · Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences · Persbericht

22/05 · Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes · Persbericht

22/05 · Europees aandelennieuws · Bolero.be

Porsche-aandeelhouders vragen meer focus van Volkswagen-CEO Blumme Volkswagen: Aandeelhouders van autofabrikant Porsche hebben Porsche-CEO Oliver Blume, die ook CEO is van Volkswagen, gevraagd om een van zijn rollen op te...

22/05 · Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline · Persbericht

Mijn selecties